Published November 15, 2012
Intarcia Therapeutics said it raised $210 million, enabling the biotechnology company to fund late-stage clinical trials for a new diabetes treatment without forming an alliance with a major drug maker. [ read more ]
Utah Business Social
Content Marketing BootcampOct 28, 2014Please join Utah Business Magazine and Adobe, along with our other sponsors: Boostability, Right ...